GLENMARK PHARMACEUTICALS
Back to Balance Sheet
|
GLENMARK PHARMACEUTICALS Last 5 Year Total Non-Current Liabilities History
[Consolidated]
Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 | |
---|---|---|---|---|---|
Total Non-Current Liabilities | ₹-357 Cr | ₹2,621 Cr | ₹1,270 Cr | ₹2,804 Cr | ₹3,033 Cr |
What is the latest Total Non-Current Liabilities ratio of GLENMARK PHARMACEUTICALS ?
Year | Total Non-Current Liabilities |
---|---|
Mar2024 | ₹-357 Cr |
Mar2023 | ₹2,621 Cr |
Mar2022 | ₹1,270 Cr |
Mar2021 | ₹2,804 Cr |
Mar2020 | ₹3,033 Cr |
How is Total Non-Current Liabilities of GLENMARK PHARMACEUTICALS Trending?
Years | Total Non-Current Liabilities | % Change | |
---|---|---|---|
Mar2024 | ₹-357 Cr | Negative | |
Mar2023 | ₹2,621 Cr | 106.48 | |
Mar2022 | ₹1,270 Cr | -54.72 | |
Mar2021 | ₹2,804 Cr | -7.56 | |
Mar2020 | ₹3,033 Cr | - |
Compare Total Non-Current Liabilities of peers of GLENMARK PHARMACEUTICALS
Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
GLENMARK PHARMACEUTICALS | ₹37,861.4 Cr | -2.6% | -4.5% | 29% | Stock Analytics | |
SUN PHARMACEUTICAL INDUSTRIES | ₹420,136.0 Cr | 6% | 4% | 9.9% | Stock Analytics | |
DIVIS LABORATORIES | ₹149,680.0 Cr | 4.7% | 0.3% | 52.4% | Stock Analytics | |
CIPLA | ₹122,394.0 Cr | 7% | 3.7% | 7.2% | Stock Analytics | |
TORRENT PHARMACEUTICALS | ₹110,159.0 Cr | 4.1% | 6.4% | 25% | Stock Analytics | |
DR REDDYS LABORATORIES | ₹97,105.6 Cr | 6.3% | 5% | -4.7% | Stock Analytics |
GLENMARK PHARMACEUTICALS Share Price vs Sensex
Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
GLENMARK PHARMACEUTICALS | -2.6% |
-4.5% |
29% |
SENSEX | 5.8% |
6.1% |
4.7% |
You may also like the below Video Courses